Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
More importantly the volume is starting to dry up. You know what comes next???
You have to pay for the promo somehow eh?
Looks like a failed promo to me...JMHO
$ODYY breakout on board!!!
$ODYY breakout on board!!!
$ODYY NEWS OUT!!!
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Las Vegas, NV, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was safe and well tolerated.
Cohort I of the MAD trial was conducted at Nucleus Network, a leading clinical research organization. Cohort I findings were evaluated by the Safety Review Committee. Eight healthy human volunteers received one dose of PRV-002 or placebo for five consecutive days followed by evaluations for abnormal responses. No severe adverse events were noted as PRV-002 was well-tolerated. Vital signs, EKG readings and breathing function were all normal. Blood labs showed no alterations associated with multi-day PRV-002 treatment. Pharmacokinetic analysis showed a direct linear relationship between drug dosing concentration and blood plasma levels for each of the five days of dosing. There was no appreciable accumulation of the drug with consecutive day treatments. Blood levels of PRV-002 were significantly lower on average with intranasal administration than what would be expected with other routes of delivery.
“After reviewing the data from MAD Cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high dose MAD portion of the Phase I clinical trial. We have unanimously approved the start of MAD Cohort II. The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.” commented Dallas Hack, MD, member of the Safety Review Committee.
Philip Ryan, MD, Principal Investigator for Nucleus Network, commented, “Low dose PRV-002 was well-tolerated when given daily for five days. There was no drug accumulation in the blood and levels were much lower than the established toxicity levels seen in the animal studies. The Safety Review Committee has confidence about the safety of the intranasal delivery of PRV-002. We look forward to completing the final high dose MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients.”
Odyssey is currently selecting clinical sites and developing the Phase II Investigator’s Brochure for the Phase II trial. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of developing a mental health disorder in youth.
The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and falls in elderly assistive-living facilities.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit our corporate social media accounts for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
https://www.globenewswire.com/newsroom/ti?nf=ODYyMTI1MyM1MDk5OTY4IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/OTk4ZjE1MGEtMWFiYi00MjNhLWIyNmMtZTZjOTMyMTNhNWZiLTUwMDA4NjI2NA==/tiny/Odyssey-Health-Inc.png
Source: Odyssey Health, Inc
$ODYY NEWS OUT!!!
Odyssey Health Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial
Las Vegas, NV, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the successful completion of safety measures for their Phase I Multi-Day Ascending Dosing (MAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For MAD Cohort I, the drug was safe and well tolerated.
Cohort I of the MAD trial was conducted at Nucleus Network, a leading clinical research organization. Cohort I findings were evaluated by the Safety Review Committee. Eight healthy human volunteers received one dose of PRV-002 or placebo for five consecutive days followed by evaluations for abnormal responses. No severe adverse events were noted as PRV-002 was well-tolerated. Vital signs, EKG readings and breathing function were all normal. Blood labs showed no alterations associated with multi-day PRV-002 treatment. Pharmacokinetic analysis showed a direct linear relationship between drug dosing concentration and blood plasma levels for each of the five days of dosing. There was no appreciable accumulation of the drug with consecutive day treatments. Blood levels of PRV-002 were significantly lower on average with intranasal administration than what would be expected with other routes of delivery.
“After reviewing the data from MAD Cohort I, I have strong confidence that PRV-002 will continue to show safety during the final, high dose MAD portion of the Phase I clinical trial. We have unanimously approved the start of MAD Cohort II. The overall low levels of PRV-002 in the blood support the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case not only can the targeted effects of the drug be more efficacious, but the drug will also likely have fewer potential side effects.” commented Dallas Hack, MD, member of the Safety Review Committee.
Philip Ryan, MD, Principal Investigator for Nucleus Network, commented, “Low dose PRV-002 was well-tolerated when given daily for five days. There was no drug accumulation in the blood and levels were much lower than the established toxicity levels seen in the animal studies. The Safety Review Committee has confidence about the safety of the intranasal delivery of PRV-002. We look forward to completing the final high dose MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients.”
Odyssey is currently selecting clinical sites and developing the Phase II Investigator’s Brochure for the Phase II trial. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of developing a mental health disorder in youth.
The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and falls in elderly assistive-living facilities.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit our corporate social media accounts for updates:
https://twitter.com/OdysseyHealth1
https://www.facebook.com/odysseyhealthinc
https://www.linkedin.com/company/odysseyhealthinc
https://www.youtube.com/channel/UCsS--v0od_fYIBu2tvqmj9Q
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
https://www.globenewswire.com/newsroom/ti?nf=ODYyMTI1MyM1MDk5OTY4IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/OTk4ZjE1MGEtMWFiYi00MjNhLWIyNmMtZTZjOTMyMTNhNWZiLTUwMDA4NjI2NA==/tiny/Odyssey-Health-Inc.png
Source: Odyssey Health, Inc
$ODYY starting to break out!!!
$ODYY starting to break out!!!
$ODYY starting to break out!!!
$ODYY NEWS OUT!!!!
Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion
Las Vegas, NV, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five consecutive days. The drug, PRV-002 was safe and well tolerated in this cohort.
The trial is being conducted by a leading clinical research organization, Avance Clinical Pty Ltd, through Nucleus Network, a Phase 1 clinical trial provider with multiple sites throughout Australia. Cohort I of MAD included eight healthy human volunteers that received one low dose of intranasal PRV-002 for five consecutive days followed by evaluations for abnormal responses. No severe adverse events were noted as PRV-002 appeared to be well-tolerated.
Dr. Jacob VanLandingham of Odyssey Health, Inc. commented, “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days. PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting.”
Concussions represent an ‘unmet’ medical need. Common settings for concussion include contact sporting events, military training and operations, motor vehicle accidents and elderly assistive-living facilities due to falls.
The Phase I MAD clinical trial is ongoing and consists of a total of 16 healthy subjects. The Phase I Single Ascending Dosing (SAD) arm has successfully been completed and was well-tolerated. Odyssey will report additional MAD results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyHealth1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
https://www.globenewswire.com/newsroom/ti?nf=ODYxNTkwOSM1MDg1MDU5IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/YzZhNzFlYWUtNDJiOC00ZWRjLTg2YzgtN2ZmYTdjMTYxMjhhLTUwMDA4NjI2NA==/tiny/Odyssey-Health-Inc.png
Source: Odyssey Health, Inc
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY NEWS OUT !!!!!
Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion
Las Vegas, NV, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five consecutive days. The drug, PRV-002 was safe and well tolerated in this cohort.
The trial is being conducted by a leading clinical research organization, Avance Clinical Pty Ltd, through Nucleus Network, a Phase 1 clinical trial provider with multiple sites throughout Australia. Cohort I of MAD included eight healthy human volunteers that received one low dose of intranasal PRV-002 for five consecutive days followed by evaluations for abnormal responses. No severe adverse events were noted as PRV-002 appeared to be well-tolerated.
Dr. Jacob VanLandingham of Odyssey Health, Inc. commented, “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days. PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting.”
Concussions represent an ‘unmet’ medical need. Common settings for concussion include contact sporting events, military training and operations, motor vehicle accidents and elderly assistive-living facilities due to falls.
The Phase I MAD clinical trial is ongoing and consists of a total of 16 healthy subjects. The Phase I Single Ascending Dosing (SAD) arm has successfully been completed and was well-tolerated. Odyssey will report additional MAD results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyHealth1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
https://www.globenewswire.com/newsroom/ti?nf=ODYxNTkwOSM1MDg1MDU5IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/YzZhNzFlYWUtNDJiOC00ZWRjLTg2YzgtN2ZmYTdjMTYxMjhhLTUwMDA4NjI2NA==/tiny/Odyssey-Health-Inc.png
Source: Odyssey Health, Inc
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY NEWS OUT !!!!
Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion
Las Vegas, NV, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five consecutive days. The drug, PRV-002 was safe and well tolerated in this cohort.
The trial is being conducted by a leading clinical research organization, Avance Clinical Pty Ltd, through Nucleus Network, a Phase 1 clinical trial provider with multiple sites throughout Australia. Cohort I of MAD included eight healthy human volunteers that received one low dose of intranasal PRV-002 for five consecutive days followed by evaluations for abnormal responses. No severe adverse events were noted as PRV-002 appeared to be well-tolerated.
Dr. Jacob VanLandingham of Odyssey Health, Inc. commented, “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days. PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting.”
Concussions represent an ‘unmet’ medical need. Common settings for concussion include contact sporting events, military training and operations, motor vehicle accidents and elderly assistive-living facilities due to falls.
The Phase I MAD clinical trial is ongoing and consists of a total of 16 healthy subjects. The Phase I Single Ascending Dosing (SAD) arm has successfully been completed and was well-tolerated. Odyssey will report additional MAD results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyHealth1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
https://www.globenewswire.com/newsroom/ti?nf=ODYxNTkwOSM1MDg1MDU5IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/YzZhNzFlYWUtNDJiOC00ZWRjLTg2YzgtN2ZmYTdjMTYxMjhhLTUwMDA4NjI2NA==/tiny/Odyssey-Health-Inc.png
Source: Odyssey Health, Inc
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY NEWS OUT!!!
Odyssey Health, Inc. Announces Positive Results from Its Phase I Multi-Day Ascending Dosing for the Treatment of Concussion
Las Vegas, NV, Aug. 10, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-improving medical products, today announces the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (MAD) arm for its Phase I Clinical Trial. Odyssey’s trial is administering PRV-002, its novel drug to treat concussion, to healthy human subjects. MAD Cohort I subjects were dosed for five consecutive days. The drug, PRV-002 was safe and well tolerated in this cohort.
The trial is being conducted by a leading clinical research organization, Avance Clinical Pty Ltd, through Nucleus Network, a Phase 1 clinical trial provider with multiple sites throughout Australia. Cohort I of MAD included eight healthy human volunteers that received one low dose of intranasal PRV-002 for five consecutive days followed by evaluations for abnormal responses. No severe adverse events were noted as PRV-002 appeared to be well-tolerated.
Dr. Jacob VanLandingham of Odyssey Health, Inc. commented, “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days. PRV-002 appears to be well-tolerated when given intranasally. If PRV-002 is found to be efficacious for concussed patients in the Phase 2/3 trials, I believe that intranasal brain-targeting will be the key to its success. So far, the intranasal drug/device combination has functioned nicely and has been well-tolerated in the clinical setting.”
Concussions represent an ‘unmet’ medical need. Common settings for concussion include contact sporting events, military training and operations, motor vehicle accidents and elderly assistive-living facilities due to falls.
The Phase I MAD clinical trial is ongoing and consists of a total of 16 healthy subjects. The Phase I Single Ascending Dosing (SAD) arm has successfully been completed and was well-tolerated. Odyssey will report additional MAD results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health Inc. (OTC: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity. For more information, visit the company’s website at www.odysseyhealthinc.com
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyHealth1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Inquiries:
Odyssey Health
info@odysseyhealthinc.com
https://www.globenewswire.com/newsroom/ti?nf=ODYxNTkwOSM1MDg1MDU5IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/YzZhNzFlYWUtNDJiOC00ZWRjLTg2YzgtN2ZmYTdjMTYxMjhhLTUwMDA4NjI2NA==/tiny/Odyssey-Health-Inc.png
Source: Odyssey Health, Inc
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY Volume picking up!!
$ODYY Volume picking up!!!
That has NOTHING to do with ODYY!! The Previous002 was acquired in 2021. The story says the former Gov has stock. The CEO says "absolutely NOT" he has ZERO shares in ODYY!!!
$ODYY MAJOR NEWS OUT PHASE1 TRIALS
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of Alzheimer’s Disease and other neuropsychiatric disorders.
“After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (MAD) portion of the Phase I clinical trial where subjects are treated once daily for five straight days. We have unanimously approved the start of MAD Cohort I. I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious the drug will likely have less potential side effects,” commented Dallas Hack, MD, member of the Safety Review Committee.
The SAD trial was conducted by Nucleus Network, a leading clinical research organization. The final cohort, Cohort III, received the highest drug dose in the SAD trial. Cohort III was unblinded and evaluated by the Safety Review Committee (SRC). Eight healthy human volunteers received one dose of PRV-002 or placebo followed by evaluations for abnormal responses. No severe adverse events were noted, as PRV-002 was well-tolerated. Vital signs, EKG readings, sleep patterns and breathing function were all normal. Blood labs showed no alterations associated with the PRV-002 treatment. Pharmacokinetic analysis showed a direct linear relationship between drug dosing concentration and blood plasma levels across all three cohorts of SAD. Blood levels of PRV-002 were significantly lower with intranasal administration to what would be expected with other routes of delivery.
Philip Ryan, MD, Principal Investigator for Nucleus Network, commented, “PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002. We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients.”
Odyssey is currently scheduling a meeting with the FDA to present the findings from the Phase 1 Trial. Phase II trial sites are being identified and study design is being created with the site’s medical leadership and the Odyssey Medical Advisors.
"I’m excited to see how well Odyssey’s drug is performing and it is proving to be safe. Now we can start the important journey to determine the efficacy of PRV-002 a much-needed solution for our military and beyond. As a proud member of Odyssey's Military Board, we are actively identifying and assisting with Phase II military trial site setup. We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” remarked, Major General(R) Jim Linder, Former Chief of Staff for the US Special Operations Command.
The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and elderly assistive-living facilities due to falls.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) (OTC Pink: ODYY) is a medical company focused on developing life enhancing medical solutions. Odyssey's corporate mission is to develop and commercialize exceptional technologies that provide meaningful medical solutions. The Company is focused on technologies that provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds to successfully complete the Phase I and Phase II/III trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
info@odysseygi.com
Local: 702-780-6559
Toll-free: 844-368-9663
Fax: 725-888-4715
ODYY NEWS OUT PHASE 1 COMPLETE!!!!
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of Alzheimer’s Disease and other neuropsychiatric disorders.
“After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (MAD) portion of the Phase I clinical trial where subjects are treated once daily for five straight days. We have unanimously approved the start of MAD Cohort I. I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious the drug will likely have less potential side effects,” commented Dallas Hack, MD, member of the Safety Review Committee.
The SAD trial was conducted by Nucleus Network, a leading clinical research organization. The final cohort, Cohort III, received the highest drug dose in the SAD trial. Cohort III was unblinded and evaluated by the Safety Review Committee (SRC). Eight healthy human volunteers received one dose of PRV-002 or placebo followed by evaluations for abnormal responses. No severe adverse events were noted, as PRV-002 was well-tolerated. Vital signs, EKG readings, sleep patterns and breathing function were all normal. Blood labs showed no alterations associated with the PRV-002 treatment. Pharmacokinetic analysis showed a direct linear relationship between drug dosing concentration and blood plasma levels across all three cohorts of SAD. Blood levels of PRV-002 were significantly lower with intranasal administration to what would be expected with other routes of delivery.
Philip Ryan, MD, Principal Investigator for Nucleus Network, commented, “PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002. We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients.”
Odyssey is currently scheduling a meeting with the FDA to present the findings from the Phase 1 Trial. Phase II trial sites are being identified and study design is being created with the site’s medical leadership and the Odyssey Medical Advisors.
"I’m excited to see how well Odyssey’s drug is performing and it is proving to be safe. Now we can start the important journey to determine the efficacy of PRV-002 a much-needed solution for our military and beyond. As a proud member of Odyssey's Military Board, we are actively identifying and assisting with Phase II military trial site setup. We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” remarked, Major General(R) Jim Linder, Former Chief of Staff for the US Special Operations Command.
The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and elderly assistive-living facilities due to falls.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) (OTC Pink: ODYY) is a medical company focused on developing life enhancing medical solutions. Odyssey's corporate mission is to develop and commercialize exceptional technologies that provide meaningful medical solutions. The Company is focused on technologies that provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds to successfully complete the Phase I and Phase II/III trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
info@odysseygi.com
Local: 702-780-6559
Toll-free: 844-368-9663
Fax: 725-888-4715
ODYY NEWS OUT PHASE ! COMPLETE!!!!
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of Alzheimer’s Disease and other neuropsychiatric disorders.
“After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (MAD) portion of the Phase I clinical trial where subjects are treated once daily for five straight days. We have unanimously approved the start of MAD Cohort I. I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious the drug will likely have less potential side effects,” commented Dallas Hack, MD, member of the Safety Review Committee.
The SAD trial was conducted by Nucleus Network, a leading clinical research organization. The final cohort, Cohort III, received the highest drug dose in the SAD trial. Cohort III was unblinded and evaluated by the Safety Review Committee (SRC). Eight healthy human volunteers received one dose of PRV-002 or placebo followed by evaluations for abnormal responses. No severe adverse events were noted, as PRV-002 was well-tolerated. Vital signs, EKG readings, sleep patterns and breathing function were all normal. Blood labs showed no alterations associated with the PRV-002 treatment. Pharmacokinetic analysis showed a direct linear relationship between drug dosing concentration and blood plasma levels across all three cohorts of SAD. Blood levels of PRV-002 were significantly lower with intranasal administration to what would be expected with other routes of delivery.
Philip Ryan, MD, Principal Investigator for Nucleus Network, commented, “PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002. We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients.”
Odyssey is currently scheduling a meeting with the FDA to present the findings from the Phase 1 Trial. Phase II trial sites are being identified and study design is being created with the site’s medical leadership and the Odyssey Medical Advisors.
"I’m excited to see how well Odyssey’s drug is performing and it is proving to be safe. Now we can start the important journey to determine the efficacy of PRV-002 a much-needed solution for our military and beyond. As a proud member of Odyssey's Military Board, we are actively identifying and assisting with Phase II military trial site setup. We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” remarked, Major General(R) Jim Linder, Former Chief of Staff for the US Special Operations Command.
The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and elderly assistive-living facilities due to falls.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) (OTC Pink: ODYY) is a medical company focused on developing life enhancing medical solutions. Odyssey's corporate mission is to develop and commercialize exceptional technologies that provide meaningful medical solutions. The Company is focused on technologies that provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds to successfully complete the Phase I and Phase II/III trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
info@odysseygi.com
Local: 702-780-6559
Toll-free: 844-368-9663
Fax: 725-888-4715
Odyssey Health, Inc. Successfully Completes Phase I Single Ascending Dosing for Intranasal Concussion Drug
Las Vegas, NV, July 12, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-enhancing medical products, today announced the completion of all three cohorts in their Phase I Single Ascending Dosing (SAD) clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. For SAD, the drug was safe and well tolerated. Concussions represent an ‘unmet’ medical need and affect millions worldwide. A single concussion can significantly increase the risk of Alzheimer’s Disease and other neuropsychiatric disorders.
“After reviewing the data from Cohort III and completing the SAD analysis, I have strong confidence that PRV-002 will continue to show safety during the Multiple Ascending Dosing (MAD) portion of the Phase I clinical trial where subjects are treated once daily for five straight days. We have unanimously approved the start of MAD Cohort I. I am especially excited to see the overall low levels of PRV-002 in the blood supporting the hypothesis that more drug is getting to the brain itself when administered with the intranasal device. If this turns out to be the case, not only can the targeted effects of the drug be more efficacious the drug will likely have less potential side effects,” commented Dallas Hack, MD, member of the Safety Review Committee.
The SAD trial was conducted by Nucleus Network, a leading clinical research organization. The final cohort, Cohort III, received the highest drug dose in the SAD trial. Cohort III was unblinded and evaluated by the Safety Review Committee (SRC). Eight healthy human volunteers received one dose of PRV-002 or placebo followed by evaluations for abnormal responses. No severe adverse events were noted, as PRV-002 was well-tolerated. Vital signs, EKG readings, sleep patterns and breathing function were all normal. Blood labs showed no alterations associated with the PRV-002 treatment. Pharmacokinetic analysis showed a direct linear relationship between drug dosing concentration and blood plasma levels across all three cohorts of SAD. Blood levels of PRV-002 were significantly lower with intranasal administration to what would be expected with other routes of delivery.
Philip Ryan, MD, Principal Investigator for Nucleus Network, commented, “PRV-002 was well-tolerated throughout the SAD portion of the Phase I trial. The SRC has confidence about the safety of the intranasal delivery of PRV-002. We look forward to completing MAD portion of the Phase I trial and assisting Odyssey with their Phase II/III design to determine the efficacy of PRV-002 for concussed patients.”
Odyssey is currently scheduling a meeting with the FDA to present the findings from the Phase 1 Trial. Phase II trial sites are being identified and study design is being created with the site’s medical leadership and the Odyssey Medical Advisors.
"I’m excited to see how well Odyssey’s drug is performing and it is proving to be safe. Now we can start the important journey to determine the efficacy of PRV-002 a much-needed solution for our military and beyond. As a proud member of Odyssey's Military Board, we are actively identifying and assisting with Phase II military trial site setup. We need a treatment to prevent the long-term consequences of concussion as far too many of our Service Members are retiring with TBI disorders that lessen their quality of life.” remarked, Major General(R) Jim Linder, Former Chief of Staff for the US Special Operations Command.
The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, children at play and elderly assistive-living facilities due to falls.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.) (OTC Pink: ODYY) is a medical company focused on developing life enhancing medical solutions. Odyssey's corporate mission is to develop and commercialize exceptional technologies that provide meaningful medical solutions. The Company is focused on technologies that provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseyhealthinc.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds to successfully complete the Phase I and Phase II/III trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
info@odysseygi.com
Local: 702-780-6559
Toll-free: 844-368-9663
Fax: 725-888-4715
https://www.globenewswire.com/newsroom/ti?
More positive news ODYY
Odyssey Health, Inc. Completes Safety Evaluation of Cohort II for Concussion Drug
Las Vegas, NV, June 29, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort II of their Phase I clinical trial. Odyssey’s trial involves administering PRV-002, the Company’s novel drug to treat concussion, to healthy human subjects. Data from Cohort II indicates that the drug was safe and well-tolerated.
The trial is being conducted at Nucleus Network, a leading clinical research organization. Cohort II was unblinded and evaluated by the Safety Review Committee. Cohort II included six healthy human volunteers who received one dose of PRV-002 or placebo followed by evaluations for abnormal responses. No severe adverse events were noted, as PRV-002 was well-tolerated. Vital signs, EKG readings, sleep patterns and breathing function were all normal. Blood labs showed no alterations associated with the PRV-002 treatment. Pharmacokinetic analysis was done by comparing these results to the animal findings of max concentration (NOEL) prior to toxicity to determine the highest concentration (Cmax) of PRV-002 and the time course (AUC) of PRV-002 concentrations in the blood to ensure that elevating the dose would be safe.
“After reviewing the data from Cohort II, I have strong confidence that PRV-002 will continue to show safety for this Phase I clinical trial as an option for the treatment of concussion. No abnormalities were seen, and we have unanimously approved the next cohort where the treatment dose will be doubled.,” commented Dallas Hack, MD, member of the Safety Review Committee.
Michael Redmond, CEO of Odyssey Health, commented, “PRV-002 continues to be well-tolerated as we increase the intranasal dose levels. We look forward to completing Phase I Clinical Trials and moving into a Phase II/III to determine the efficacy of PRV-002 for concussed patients. I believe that intranasal brain-targeting will be the key to its success. We are currently in discussions with military training sites for our Phase II/III clinical trials.”
The Phase I clinical trial is ongoing and consists of 40 healthy subjects. The trial has a single ascending dose and a multi ascending dose component to it. Odyssey will report additional results as they become available. Odyssey is currently scheduling a meeting with the FDA to present the findings from this Phase I trial.
Concussions represent an ‘unmet’ medical need and affect millions worldwide. The global market for concussion treatment was valued at $6.9 billion in 2020 and is forecasted to reach $8.9 billion by 2027, according to Grandview Research. Common settings for concussion include contact sports, military training and operations, motor vehicle accidents, and elderly assisted-living facilities due to falls.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Health, Inc. (OTC Pink: ODYY) is a medical company with a focus in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and develop distinct assets, intellectual property, and exceptional technologies that provide meaningful medical solutions. The Company is focused on areas that have an identified technological advantage, provide superior clinical utility, and have a substantial market opportunity.
We encourage our shareholders to visit: https://odysseygi.com/ or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the Phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Looks like someone took a nice position today $ODYY!!!!!
TBT know it well, been in this for a while $WNRS!!!!!!
$ODYY HUGE NEWS!! Phase 1 trials are in!!!!
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. Each year, there are over three million reported concussions in men, women and children in the United States and over 20 million worldwide. Concussions represent an ‘unmet’ medical need, as there is no FDA approved treatment.
“Based on our animal data and after reviewing our initial Phase I trial safety reports we are optimistic that PRV-002 will be a safe option for the treatment of concussion. We look forward to completing the Phase I trial and presenting our findings to the FDA. Following FDA review we intend to initiate a Phase II clinical trial in the US starting with our military. We have created a military advisory board to assist with this effort.” commented Michael Redmond, CEO of Odyssey Health, Inc.
The trial is being conducted at a leading Clinical Research Organization, Nucleus Network. Enrollment of Phase I healthy human subjects is done through an intense health screening process. Initially the subject is asked to acknowledge any known risks that may affect their trial performance. This is followed by a full health assessment to establish the subjects’ physical suitability including measurements for blood pressure, heart rate, lung capacity, and extensive blood work analysis.
The group reported on represents five healthy subjects that received a single dose of PRV-002. The following health measurements were conducted: vital signs, ECG, spirometry, nasal examination, a questionnaire and sleepiness scale. There were no serious adverse events reported.
Dr. Philip Ryan of Nucleus Networks commented, “Concussion is a condition that can have many debilitating long-term effects and cause significant impact in the lives of many people. Nucleus Network is proud to play a part in evaluating a treatment that improves our understanding of concussions and may one day lead to improved health outcomes for sufferers.”
The Phase I clinical trial is ongoing and consists of 48 healthy subjects. The Phase I trial has a single ascending dose and a multi ascending dose component to it. Odyssey will report additional results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
$ODYY HUGE NEWS!! Phase 1 trials are in!!!!
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. Each year, there are over three million reported concussions in men, women and children in the United States and over 20 million worldwide. Concussions represent an ‘unmet’ medical need, as there is no FDA approved treatment.
“Based on our animal data and after reviewing our initial Phase I trial safety reports we are optimistic that PRV-002 will be a safe option for the treatment of concussion. We look forward to completing the Phase I trial and presenting our findings to the FDA. Following FDA review we intend to initiate a Phase II clinical trial in the US starting with our military. We have created a military advisory board to assist with this effort.” commented Michael Redmond, CEO of Odyssey Health, Inc.
The trial is being conducted at a leading Clinical Research Organization, Nucleus Network. Enrollment of Phase I healthy human subjects is done through an intense health screening process. Initially the subject is asked to acknowledge any known risks that may affect their trial performance. This is followed by a full health assessment to establish the subjects’ physical suitability including measurements for blood pressure, heart rate, lung capacity, and extensive blood work analysis.
The group reported on represents five healthy subjects that received a single dose of PRV-002. The following health measurements were conducted: vital signs, ECG, spirometry, nasal examination, a questionnaire and sleepiness scale. There were no serious adverse events reported.
Dr. Philip Ryan of Nucleus Networks commented, “Concussion is a condition that can have many debilitating long-term effects and cause significant impact in the lives of many people. Nucleus Network is proud to play a part in evaluating a treatment that improves our understanding of concussions and may one day lead to improved health outcomes for sufferers.”
The Phase I clinical trial is ongoing and consists of 48 healthy subjects. The Phase I trial has a single ascending dose and a multi ascending dose component to it. Odyssey will report additional results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
$ODYY HUGE NEWS!! Phase 1 trials are in!!!!
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. Each year, there are over three million reported concussions in men, women and children in the United States and over 20 million worldwide. Concussions represent an ‘unmet’ medical need, as there is no FDA approved treatment.
“Based on our animal data and after reviewing our initial Phase I trial safety reports we are optimistic that PRV-002 will be a safe option for the treatment of concussion. We look forward to completing the Phase I trial and presenting our findings to the FDA. Following FDA review we intend to initiate a Phase II clinical trial in the US starting with our military. We have created a military advisory board to assist with this effort.” commented Michael Redmond, CEO of Odyssey Health, Inc.
The trial is being conducted at a leading Clinical Research Organization, Nucleus Network. Enrollment of Phase I healthy human subjects is done through an intense health screening process. Initially the subject is asked to acknowledge any known risks that may affect their trial performance. This is followed by a full health assessment to establish the subjects’ physical suitability including measurements for blood pressure, heart rate, lung capacity, and extensive blood work analysis.
The group reported on represents five healthy subjects that received a single dose of PRV-002. The following health measurements were conducted: vital signs, ECG, spirometry, nasal examination, a questionnaire and sleepiness scale. There were no serious adverse events reported.
Dr. Philip Ryan of Nucleus Networks commented, “Concussion is a condition that can have many debilitating long-term effects and cause significant impact in the lives of many people. Nucleus Network is proud to play a part in evaluating a treatment that improves our understanding of concussions and may one day lead to improved health outcomes for sufferers.”
The Phase I clinical trial is ongoing and consists of 48 healthy subjects. The Phase I trial has a single ascending dose and a multi ascending dose component to it. Odyssey will report additional results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
$ODYY HUGE NEWS!! Phase 1 trials are in!!!!
Odyssey Health, Inc. Announces Positive Results from Initial Phase I Clinical Trial Subjects for Concussion Drug
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their Phase I clinical trial. Odyssey’s trial is administering PRV-002, their novel drug to treat concussion, to healthy human subjects. Thus far the drug has shown to be safe and well tolerated. Each year, there are over three million reported concussions in men, women and children in the United States and over 20 million worldwide. Concussions represent an ‘unmet’ medical need, as there is no FDA approved treatment.
“Based on our animal data and after reviewing our initial Phase I trial safety reports we are optimistic that PRV-002 will be a safe option for the treatment of concussion. We look forward to completing the Phase I trial and presenting our findings to the FDA. Following FDA review we intend to initiate a Phase II clinical trial in the US starting with our military. We have created a military advisory board to assist with this effort.” commented Michael Redmond, CEO of Odyssey Health, Inc.
The trial is being conducted at a leading Clinical Research Organization, Nucleus Network. Enrollment of Phase I healthy human subjects is done through an intense health screening process. Initially the subject is asked to acknowledge any known risks that may affect their trial performance. This is followed by a full health assessment to establish the subjects’ physical suitability including measurements for blood pressure, heart rate, lung capacity, and extensive blood work analysis.
The group reported on represents five healthy subjects that received a single dose of PRV-002. The following health measurements were conducted: vital signs, ECG, spirometry, nasal examination, a questionnaire and sleepiness scale. There were no serious adverse events reported.
Dr. Philip Ryan of Nucleus Networks commented, “Concussion is a condition that can have many debilitating long-term effects and cause significant impact in the lives of many people. Nucleus Network is proud to play a part in evaluating a treatment that improves our understanding of concussions and may one day lead to improved health outcomes for sufferers.”
The Phase I clinical trial is ongoing and consists of 48 healthy subjects. The Phase I trial has a single ascending dose and a multi ascending dose component to it. Odyssey will report additional results as they become available.
About Odyssey Health Inc. (formerly Odyssey Group International, Inc.)
Odyssey Group International, Inc. (OTC Pink: ODYY) is a technology and asset acquisition company with a focus in the area of life saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful medical solutions. The Company is focused on building and acquiring assets in areas that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity and provide solid returns to its valued shareholders and partners.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow.
About Nucleus Network
Nucleus Network is the only multi-site Phase 1 clinical trials provider located in Australia and the USA. Nucleus Network provides high-quality, first-in-human and early-phase trials for biotechnology and pharmaceutical companies across the USA, Europe and Asia. Located within cutting-edge health precincts, their cost-effective, accelerated clinical development solutions are supported by advanced technology, clinical excellence, and research expertise.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase I trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
$ODYY NEWS OUT!!!
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Company’s prestigious Military Advisory Board. Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial.
“Too many service members and veterans are suffering from post-concussive events, while their families are suffering as they watch and provide care. There remains an urgent need for a concussion treatment at the point of injury that immediately treats the initial injury, speeds recovery, and potentially diminishes its long-term effects. We are obligated to pursue treatments that improve a service member’s, and their families’, well-being through their service commitment and beyond.”
Vice Admiral (r) Szymanski has led and served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for over 36 years. He most recently served as the Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW). In both roles he was responsible for the manning, equipping, and training, and employment of Navy SEAL and joint special operations forces, of 11,000 and 73,000 uniformed and civilian personnel, respectively.
He has commanded a SEAL Team, Special Boat Team, a Squadron at a Special Mission Unit, and a Special Operations Joint Task Force. His recent assignments as a flag officer were Deputy Commander USSOCOM, Commander Naval Special Warfare Command, Assistant Commanding General Joint Special Operations Command and Deputy Commander of NATO Special Operations Component Command – Afghanistan. Szymanski attended the U.S. Naval Academy Preparatory School and graduated from the United States Naval Academy in 1985.
Keenly aware of the detrimental effects of invisible wounds on Force and Family Readiness, he established policy to cognitively baseline the entire Special Operations community as well as created initiatives to prevent, protect, recover, and enhance cognitive performance and brain health.
Studies estimate that up to 3.8 million people in the United States experience a concussion each year. It is also estimated that from 30 to 50 percent of concussions are unreported and untreated.
About Odyssey Health, Inc.
Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility and have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachment
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUyNTM5OCM0ODYwMDg1IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/NzcyOWIyZTYtMzkwOC00YzQ3LTgwY2YtNzhiOGU2NDU0ZjEzLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Vice Admiral (r) Timothy Szymanski
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY NEWS OUT!!!
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Company’s prestigious Military Advisory Board. Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial.
“Too many service members and veterans are suffering from post-concussive events, while their families are suffering as they watch and provide care. There remains an urgent need for a concussion treatment at the point of injury that immediately treats the initial injury, speeds recovery, and potentially diminishes its long-term effects. We are obligated to pursue treatments that improve a service member’s, and their families’, well-being through their service commitment and beyond.”
Vice Admiral (r) Szymanski has led and served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for over 36 years. He most recently served as the Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW). In both roles he was responsible for the manning, equipping, and training, and employment of Navy SEAL and joint special operations forces, of 11,000 and 73,000 uniformed and civilian personnel, respectively.
He has commanded a SEAL Team, Special Boat Team, a Squadron at a Special Mission Unit, and a Special Operations Joint Task Force. His recent assignments as a flag officer were Deputy Commander USSOCOM, Commander Naval Special Warfare Command, Assistant Commanding General Joint Special Operations Command and Deputy Commander of NATO Special Operations Component Command – Afghanistan. Szymanski attended the U.S. Naval Academy Preparatory School and graduated from the United States Naval Academy in 1985.
Keenly aware of the detrimental effects of invisible wounds on Force and Family Readiness, he established policy to cognitively baseline the entire Special Operations community as well as created initiatives to prevent, protect, recover, and enhance cognitive performance and brain health.
Studies estimate that up to 3.8 million people in the United States experience a concussion each year. It is also estimated that from 30 to 50 percent of concussions are unreported and untreated.
About Odyssey Health, Inc.
Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility and have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachment
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUyNTM5OCM0ODYwMDg1IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/NzcyOWIyZTYtMzkwOC00YzQ3LTgwY2YtNzhiOGU2NDU0ZjEzLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Vice Admiral (r) Timothy Szymanski
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
NEWS OUT!!! $ODYY
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Irvine, CA, April 20, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing a proprietary drug compound to treat concussion, is honored to welcome Vice Admiral (r) Timothy Szymanski to the Company’s prestigious Military Advisory Board. Odyssey’s drug candidate, PRV-002 is currently in a phase 1 clinical trial.
“Too many service members and veterans are suffering from post-concussive events, while their families are suffering as they watch and provide care. There remains an urgent need for a concussion treatment at the point of injury that immediately treats the initial injury, speeds recovery, and potentially diminishes its long-term effects. We are obligated to pursue treatments that improve a service member’s, and their families’, well-being through their service commitment and beyond.”
Vice Admiral (r) Szymanski has led and served in many Navy and Joint Special Operations assignments as a Navy Special Warfare Officer (SEAL) for over 36 years. He most recently served as the Deputy Commander for United States Special Operations Command (USSOCOM) after serving as the Commander of Naval Special Warfare (NSW). In both roles he was responsible for the manning, equipping, and training, and employment of Navy SEAL and joint special operations forces, of 11,000 and 73,000 uniformed and civilian personnel, respectively.
He has commanded a SEAL Team, Special Boat Team, a Squadron at a Special Mission Unit, and a Special Operations Joint Task Force. His recent assignments as a flag officer were Deputy Commander USSOCOM, Commander Naval Special Warfare Command, Assistant Commanding General Joint Special Operations Command and Deputy Commander of NATO Special Operations Component Command – Afghanistan. Szymanski attended the U.S. Naval Academy Preparatory School and graduated from the United States Naval Academy in 1985.
Keenly aware of the detrimental effects of invisible wounds on Force and Family Readiness, he established policy to cognitively baseline the entire Special Operations community as well as created initiatives to prevent, protect, recover, and enhance cognitive performance and brain health.
Studies estimate that up to 3.8 million people in the United States experience a concussion each year. It is also estimated that from 30 to 50 percent of concussions are unreported and untreated.
About Odyssey Health, Inc.
Odyssey Health, Inc., formerly known as Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility and have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachment
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUyNTM5OCM0ODYwMDg1IzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/NzcyOWIyZTYtMzkwOC00YzQ3LTgwY2YtNzhiOGU2NDU0ZjEzLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Health Welcomes United States Vice Admiral (r) Timothy Szymanski to Military Advisory Board
Vice Admiral (r) Timothy Szymanski
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY NEWS OUT!!
Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
Irvine, CA, March 31, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those who suffer. Odyssey’s drug candidate, PRV-002 is intended to treat concussion and is currently in a phase 1 clinical trial. The initial members of the Military Advisory Board are:
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
“We have lived the consequences of TBI on the battlefield. Treatment at the point of injury and beyond is a challenge we must passionately and aggressively pursue.”
Francis Beaudette: Commanding General US Army Special Operations Command (r)
“Leaders at all levels have a moral and professional obligation to do everything possible to ensure and protect the comprehensive brain health of their Soldiers. It matters now, and will matter long after their service commitment to the Nation is complete. These responsibilities can only be fully accomplished through an active offense. The era of passive defense, or just simply hoping for the best, is long gone. Preparation and timely and accurate response are critical, now more than ever.”
Paul Toolan: Lieutenant Colonel (r)
“As I spend more and more time with retired and separated service members, I continue to be troubled by how many of them are struggling with neurological/cognitive issues on a spectrum from mild to severe. Having an opportunity to advocate for a treatment that could prevent these outcomes and improve the lives of the people who preserve our way of life, is an honor and a privilege.”
According to the CDC, millions of concussions occur each year in the United States and especially in the military.
“We are honored to have such distinguished and passionate leaders in our military join us in this much needed effort to find a viable treatment for brain injury,” commented Michael Redmond, CEO of Odyssey Group International.
Founding Members of the Military Advisory Board:
James Linder: Jim Linder is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist. A US General Officer with over three decades of direct command leadership around the globe.
Originally from South Carolina, Jim graduated from Clemson University as a Distinguished Military Graduate. His service has taken him to over 71 countries across Europe, into South East Asia, throughout Africa and the Middle East, and Central and South America.
As a General Officer, he created new cutting-edge capabilities and accelerated the growth of highly skilled Afghan Special Forces. He also led and directed all US special operations across the African continent, while interacting with US interagency and African leaders to achieve US national security goals. He adeptly applied new ideas as commandant of the Army’s premier Center of Excellence for selecting and training Special Operations Forces, and was the commander of all US and NATO special operations forces in combat in Afghanistan during a critical period of transition. Most recently, he achieved value-driven results managing a complex and agile organization of 80k persons with a $13.4B government operating budget as the Chief of Staff for US Special Operations Command.
Major General (retired) Linder is currently the President of Tenax Aerospace and has master’s degrees in International Relations from Webster University and also National Security and Strategic Studies from the US Naval War College.
Francis Beaudette: Over the course of his 32-year career in Army and Joint assignments, the majority of it as a Green Beret, Francis “Fran” M. Beaudette served with high performing organizations at varying levels, from a 12-man Special Forces ‘A-team’ to the 36,000-Soldier and Civilian US Army Special Operations Command.
His recent assignments were Deputy Commanding General of the 1st Armored Division, Assistant Commanding General of JSOC, CG of 1st Special Forces Command and Commanding General of the US Army Special Operations Command.
His operational assignments, totaling six years of deployed time, include the first Gulf War; comprehensive Africa experience to include noncombatant evacuation operations in Sierra Leone and the Congo; multiple peacekeeping operations in Kosovo; numerous deployments in Iraq, Afghanistan, the Philippines and Jordan, all during eras of war, turmoil or crisis.
Fran was a distinguished academic and military graduate from the Citadel and holds a MA in Military Arts and Science from the US Army Command & General Staff College and a MS in Strategic Studies from the US Army War College.
Paul Toolan: Lieutenant Colonel (LTC) Paul Toolan joined the Army as a Private in 1986. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the US Army. He is a Special Forces Airborne Ranger and started his Special Forces career as a Detachment Commander in 3rd Special Forces Group at Fort Bragg. He has held nearly a dozen leadership positions in multiple Special Forces Groups, including Detachment Commander, Company Executive Officer, Battalion Operations Officer, Support Company Commander, Company Commander, Group Operations Officer, Group Executive Officer, Battalion Commander, Chief of the Special Forces Training Division, and the Director of Operations at 1st Special Forces Command. He has worked at the National Counter-Terrorism Center as a Special Forces advisor and worked as a Special Forces consultant in the United States Army Special Operations Commander’s Initiatives Group. He last duty assignment was the Deputy Commander of the 1st Special Warfare Training Group at Fort Bragg, North Carolina, where Green Berets are assessed, selected and trained.
Since retiring from military service, Paul has dedicated himself to helping Special Operators address the effects of life in Special Operations such as post-traumatic stress (PTS), traumatic brain injury (TBI) and Operator Syndrome (overstimulated sympathetic nervous system) by facilitating access to treatment innovations.
Having served for many decades in leadership roles, the members of this Board have a passion for helping active military personnel and our Veterans. They recognize the unique medical conditions they deal with and how important it is that they receive specialty care. Concussions have been linked to the increased incidence of PTSD, early-stage dementia and suicidal ideation. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and safer.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachments
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUxMzM5NiM0ODI2NjgzIzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/MzQxNTA4NWItMmVjZC00YTQ0LWExYzMtZGExNzM1OGUzNDVhLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Group International Announces Formation of Military Advisory Board
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
Odyssey Group International Announces Formation of Military Advisory Board
Francis Beaudette: Commanding General US Army Special Operations Command (r)
Odyssey Group International Announces Formation of Military Advisory Board
Paul Toolan: Lieutenant Colonel (r)
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
NEWS OUT !!!!
Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
Irvine, CA, March 31, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those who suffer. Odyssey’s drug candidate, PRV-002 is intended to treat concussion and is currently in a phase 1 clinical trial. The initial members of the Military Advisory Board are:
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
“We have lived the consequences of TBI on the battlefield. Treatment at the point of injury and beyond is a challenge we must passionately and aggressively pursue.”
Francis Beaudette: Commanding General US Army Special Operations Command (r)
“Leaders at all levels have a moral and professional obligation to do everything possible to ensure and protect the comprehensive brain health of their Soldiers. It matters now, and will matter long after their service commitment to the Nation is complete. These responsibilities can only be fully accomplished through an active offense. The era of passive defense, or just simply hoping for the best, is long gone. Preparation and timely and accurate response are critical, now more than ever.”
Paul Toolan: Lieutenant Colonel (r)
“As I spend more and more time with retired and separated service members, I continue to be troubled by how many of them are struggling with neurological/cognitive issues on a spectrum from mild to severe. Having an opportunity to advocate for a treatment that could prevent these outcomes and improve the lives of the people who preserve our way of life, is an honor and a privilege.”
According to the CDC, millions of concussions occur each year in the United States and especially in the military.
“We are honored to have such distinguished and passionate leaders in our military join us in this much needed effort to find a viable treatment for brain injury,” commented Michael Redmond, CEO of Odyssey Group International.
Founding Members of the Military Advisory Board:
James Linder: Jim Linder is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist. A US General Officer with over three decades of direct command leadership around the globe.
Originally from South Carolina, Jim graduated from Clemson University as a Distinguished Military Graduate. His service has taken him to over 71 countries across Europe, into South East Asia, throughout Africa and the Middle East, and Central and South America.
As a General Officer, he created new cutting-edge capabilities and accelerated the growth of highly skilled Afghan Special Forces. He also led and directed all US special operations across the African continent, while interacting with US interagency and African leaders to achieve US national security goals. He adeptly applied new ideas as commandant of the Army’s premier Center of Excellence for selecting and training Special Operations Forces, and was the commander of all US and NATO special operations forces in combat in Afghanistan during a critical period of transition. Most recently, he achieved value-driven results managing a complex and agile organization of 80k persons with a $13.4B government operating budget as the Chief of Staff for US Special Operations Command.
Major General (retired) Linder is currently the President of Tenax Aerospace and has master’s degrees in International Relations from Webster University and also National Security and Strategic Studies from the US Naval War College.
Francis Beaudette: Over the course of his 32-year career in Army and Joint assignments, the majority of it as a Green Beret, Francis “Fran” M. Beaudette served with high performing organizations at varying levels, from a 12-man Special Forces ‘A-team’ to the 36,000-Soldier and Civilian US Army Special Operations Command.
His recent assignments were Deputy Commanding General of the 1st Armored Division, Assistant Commanding General of JSOC, CG of 1st Special Forces Command and Commanding General of the US Army Special Operations Command.
His operational assignments, totaling six years of deployed time, include the first Gulf War; comprehensive Africa experience to include noncombatant evacuation operations in Sierra Leone and the Congo; multiple peacekeeping operations in Kosovo; numerous deployments in Iraq, Afghanistan, the Philippines and Jordan, all during eras of war, turmoil or crisis.
Fran was a distinguished academic and military graduate from the Citadel and holds a MA in Military Arts and Science from the US Army Command & General Staff College and a MS in Strategic Studies from the US Army War College.
Paul Toolan: Lieutenant Colonel (LTC) Paul Toolan joined the Army as a Private in 1986. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the US Army. He is a Special Forces Airborne Ranger and started his Special Forces career as a Detachment Commander in 3rd Special Forces Group at Fort Bragg. He has held nearly a dozen leadership positions in multiple Special Forces Groups, including Detachment Commander, Company Executive Officer, Battalion Operations Officer, Support Company Commander, Company Commander, Group Operations Officer, Group Executive Officer, Battalion Commander, Chief of the Special Forces Training Division, and the Director of Operations at 1st Special Forces Command. He has worked at the National Counter-Terrorism Center as a Special Forces advisor and worked as a Special Forces consultant in the United States Army Special Operations Commander’s Initiatives Group. He last duty assignment was the Deputy Commander of the 1st Special Warfare Training Group at Fort Bragg, North Carolina, where Green Berets are assessed, selected and trained.
Since retiring from military service, Paul has dedicated himself to helping Special Operators address the effects of life in Special Operations such as post-traumatic stress (PTS), traumatic brain injury (TBI) and Operator Syndrome (overstimulated sympathetic nervous system) by facilitating access to treatment innovations.
Having served for many decades in leadership roles, the members of this Board have a passion for helping active military personnel and our Veterans. They recognize the unique medical conditions they deal with and how important it is that they receive specialty care. Concussions have been linked to the increased incidence of PTSD, early-stage dementia and suicidal ideation. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and safer.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachments
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUxMzM5NiM0ODI2NjgzIzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/MzQxNTA4NWItMmVjZC00YTQ0LWExYzMtZGExNzM1OGUzNDVhLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Group International Announces Formation of Military Advisory Board
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
Odyssey Group International Announces Formation of Military Advisory Board
Francis Beaudette: Commanding General US Army Special Operations Command (r)
Odyssey Group International Announces Formation of Military Advisory Board
Paul Toolan: Lieutenant Colonel (r)
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Back to News Headlines
Other Financial Information
Recent News & Disclosure Filings
Recent SEC Filings
Pink Open Market Logo
Pink Current Information
Transfer Agent Verified IconTransfer Agent Verified
Shell Risk IconShell Risk
Independent Directors IconIndependent Directors
$ODYY NEWS OUT !!!!
Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
Irvine, CA, March 31, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those who suffer. Odyssey’s drug candidate, PRV-002 is intended to treat concussion and is currently in a phase 1 clinical trial. The initial members of the Military Advisory Board are:
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
“We have lived the consequences of TBI on the battlefield. Treatment at the point of injury and beyond is a challenge we must passionately and aggressively pursue.”
Francis Beaudette: Commanding General US Army Special Operations Command (r)
“Leaders at all levels have a moral and professional obligation to do everything possible to ensure and protect the comprehensive brain health of their Soldiers. It matters now, and will matter long after their service commitment to the Nation is complete. These responsibilities can only be fully accomplished through an active offense. The era of passive defense, or just simply hoping for the best, is long gone. Preparation and timely and accurate response are critical, now more than ever.”
Paul Toolan: Lieutenant Colonel (r)
“As I spend more and more time with retired and separated service members, I continue to be troubled by how many of them are struggling with neurological/cognitive issues on a spectrum from mild to severe. Having an opportunity to advocate for a treatment that could prevent these outcomes and improve the lives of the people who preserve our way of life, is an honor and a privilege.”
According to the CDC, millions of concussions occur each year in the United States and especially in the military.
“We are honored to have such distinguished and passionate leaders in our military join us in this much needed effort to find a viable treatment for brain injury,” commented Michael Redmond, CEO of Odyssey Group International.
Founding Members of the Military Advisory Board:
James Linder: Jim Linder is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist. A US General Officer with over three decades of direct command leadership around the globe.
Originally from South Carolina, Jim graduated from Clemson University as a Distinguished Military Graduate. His service has taken him to over 71 countries across Europe, into South East Asia, throughout Africa and the Middle East, and Central and South America.
As a General Officer, he created new cutting-edge capabilities and accelerated the growth of highly skilled Afghan Special Forces. He also led and directed all US special operations across the African continent, while interacting with US interagency and African leaders to achieve US national security goals. He adeptly applied new ideas as commandant of the Army’s premier Center of Excellence for selecting and training Special Operations Forces, and was the commander of all US and NATO special operations forces in combat in Afghanistan during a critical period of transition. Most recently, he achieved value-driven results managing a complex and agile organization of 80k persons with a $13.4B government operating budget as the Chief of Staff for US Special Operations Command.
Major General (retired) Linder is currently the President of Tenax Aerospace and has master’s degrees in International Relations from Webster University and also National Security and Strategic Studies from the US Naval War College.
Francis Beaudette: Over the course of his 32-year career in Army and Joint assignments, the majority of it as a Green Beret, Francis “Fran” M. Beaudette served with high performing organizations at varying levels, from a 12-man Special Forces ‘A-team’ to the 36,000-Soldier and Civilian US Army Special Operations Command.
His recent assignments were Deputy Commanding General of the 1st Armored Division, Assistant Commanding General of JSOC, CG of 1st Special Forces Command and Commanding General of the US Army Special Operations Command.
His operational assignments, totaling six years of deployed time, include the first Gulf War; comprehensive Africa experience to include noncombatant evacuation operations in Sierra Leone and the Congo; multiple peacekeeping operations in Kosovo; numerous deployments in Iraq, Afghanistan, the Philippines and Jordan, all during eras of war, turmoil or crisis.
Fran was a distinguished academic and military graduate from the Citadel and holds a MA in Military Arts and Science from the US Army Command & General Staff College and a MS in Strategic Studies from the US Army War College.
Paul Toolan: Lieutenant Colonel (LTC) Paul Toolan joined the Army as a Private in 1986. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the US Army. He is a Special Forces Airborne Ranger and started his Special Forces career as a Detachment Commander in 3rd Special Forces Group at Fort Bragg. He has held nearly a dozen leadership positions in multiple Special Forces Groups, including Detachment Commander, Company Executive Officer, Battalion Operations Officer, Support Company Commander, Company Commander, Group Operations Officer, Group Executive Officer, Battalion Commander, Chief of the Special Forces Training Division, and the Director of Operations at 1st Special Forces Command. He has worked at the National Counter-Terrorism Center as a Special Forces advisor and worked as a Special Forces consultant in the United States Army Special Operations Commander’s Initiatives Group. He last duty assignment was the Deputy Commander of the 1st Special Warfare Training Group at Fort Bragg, North Carolina, where Green Berets are assessed, selected and trained.
Since retiring from military service, Paul has dedicated himself to helping Special Operators address the effects of life in Special Operations such as post-traumatic stress (PTS), traumatic brain injury (TBI) and Operator Syndrome (overstimulated sympathetic nervous system) by facilitating access to treatment innovations.
Having served for many decades in leadership roles, the members of this Board have a passion for helping active military personnel and our Veterans. They recognize the unique medical conditions they deal with and how important it is that they receive specialty care. Concussions have been linked to the increased incidence of PTSD, early-stage dementia and suicidal ideation. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and safer.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachments
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUxMzM5NiM0ODI2NjgzIzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/MzQxNTA4NWItMmVjZC00YTQ0LWExYzMtZGExNzM1OGUzNDVhLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Group International Announces Formation of Military Advisory Board
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
Odyssey Group International Announces Formation of Military Advisory Board
Francis Beaudette: Commanding General US Army Special Operations Command (r)
Odyssey Group International Announces Formation of Military Advisory Board
Paul Toolan: Lieutenant Colonel (r)
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
$ODYY NEWS OUT !!!!!!
Odyssey Group International Announces Formation of Military Advisory Board and Welcomes Prestigious Members to Assist with Concussion Drug Development
Irvine, CA, March 31, 2022 (GLOBE NEWSWIRE) -- Odyssey Group International, Inc. (OTC Pink: ODYY) (the "Company" or "Odyssey"), a company focused on developing unique, life-saving medical products, today announced the formation of its Military Advisory Board with the appointment of prestigious leaders in the field. Garnering experience and insight from these leaders in our military service branches will provide critical insight to traumatic brain injuries and the effects it has on those who suffer. Odyssey’s drug candidate, PRV-002 is intended to treat concussion and is currently in a phase 1 clinical trial. The initial members of the Military Advisory Board are:
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
“We have lived the consequences of TBI on the battlefield. Treatment at the point of injury and beyond is a challenge we must passionately and aggressively pursue.”
Francis Beaudette: Commanding General US Army Special Operations Command (r)
“Leaders at all levels have a moral and professional obligation to do everything possible to ensure and protect the comprehensive brain health of their Soldiers. It matters now, and will matter long after their service commitment to the Nation is complete. These responsibilities can only be fully accomplished through an active offense. The era of passive defense, or just simply hoping for the best, is long gone. Preparation and timely and accurate response are critical, now more than ever.”
Paul Toolan: Lieutenant Colonel (r)
“As I spend more and more time with retired and separated service members, I continue to be troubled by how many of them are struggling with neurological/cognitive issues on a spectrum from mild to severe. Having an opportunity to advocate for a treatment that could prevent these outcomes and improve the lives of the people who preserve our way of life, is an honor and a privilege.”
According to the CDC, millions of concussions occur each year in the United States and especially in the military.
“We are honored to have such distinguished and passionate leaders in our military join us in this much needed effort to find a viable treatment for brain injury,” commented Michael Redmond, CEO of Odyssey Group International.
Founding Members of the Military Advisory Board:
James Linder: Jim Linder is a recognized leader in the world of Special Operations and Intelligence organizations as a high performing and skilled strategist. A US General Officer with over three decades of direct command leadership around the globe.
Originally from South Carolina, Jim graduated from Clemson University as a Distinguished Military Graduate. His service has taken him to over 71 countries across Europe, into South East Asia, throughout Africa and the Middle East, and Central and South America.
As a General Officer, he created new cutting-edge capabilities and accelerated the growth of highly skilled Afghan Special Forces. He also led and directed all US special operations across the African continent, while interacting with US interagency and African leaders to achieve US national security goals. He adeptly applied new ideas as commandant of the Army’s premier Center of Excellence for selecting and training Special Operations Forces, and was the commander of all US and NATO special operations forces in combat in Afghanistan during a critical period of transition. Most recently, he achieved value-driven results managing a complex and agile organization of 80k persons with a $13.4B government operating budget as the Chief of Staff for US Special Operations Command.
Major General (retired) Linder is currently the President of Tenax Aerospace and has master’s degrees in International Relations from Webster University and also National Security and Strategic Studies from the US Naval War College.
Francis Beaudette: Over the course of his 32-year career in Army and Joint assignments, the majority of it as a Green Beret, Francis “Fran” M. Beaudette served with high performing organizations at varying levels, from a 12-man Special Forces ‘A-team’ to the 36,000-Soldier and Civilian US Army Special Operations Command.
His recent assignments were Deputy Commanding General of the 1st Armored Division, Assistant Commanding General of JSOC, CG of 1st Special Forces Command and Commanding General of the US Army Special Operations Command.
His operational assignments, totaling six years of deployed time, include the first Gulf War; comprehensive Africa experience to include noncombatant evacuation operations in Sierra Leone and the Congo; multiple peacekeeping operations in Kosovo; numerous deployments in Iraq, Afghanistan, the Philippines and Jordan, all during eras of war, turmoil or crisis.
Fran was a distinguished academic and military graduate from the Citadel and holds a MA in Military Arts and Science from the US Army Command & General Staff College and a MS in Strategic Studies from the US Army War College.
Paul Toolan: Lieutenant Colonel (LTC) Paul Toolan joined the Army as a Private in 1986. Over the course of more than three decades in uniform, he has risen through the ranks and completed every elite school in the US Army. He is a Special Forces Airborne Ranger and started his Special Forces career as a Detachment Commander in 3rd Special Forces Group at Fort Bragg. He has held nearly a dozen leadership positions in multiple Special Forces Groups, including Detachment Commander, Company Executive Officer, Battalion Operations Officer, Support Company Commander, Company Commander, Group Operations Officer, Group Executive Officer, Battalion Commander, Chief of the Special Forces Training Division, and the Director of Operations at 1st Special Forces Command. He has worked at the National Counter-Terrorism Center as a Special Forces advisor and worked as a Special Forces consultant in the United States Army Special Operations Commander’s Initiatives Group. He last duty assignment was the Deputy Commander of the 1st Special Warfare Training Group at Fort Bragg, North Carolina, where Green Berets are assessed, selected and trained.
Since retiring from military service, Paul has dedicated himself to helping Special Operators address the effects of life in Special Operations such as post-traumatic stress (PTS), traumatic brain injury (TBI) and Operator Syndrome (overstimulated sympathetic nervous system) by facilitating access to treatment innovations.
Having served for many decades in leadership roles, the members of this Board have a passion for helping active military personnel and our Veterans. They recognize the unique medical conditions they deal with and how important it is that they receive specialty care. Concussions have been linked to the increased incidence of PTSD, early-stage dementia and suicidal ideation. Odyssey is developing the first pharmaceutical to treat concussion in the acute phase of injury. A field deliverable intranasal device filled with their drug, PRV-002 can be kept in the medic’s bag or the soldier’s pocket for “buddy” aid immediately following a concussion. Reducing inflammation of the brain early on can significantly improve outcomes and return our soldiers back to action faster and safer.
About Odyssey Group International, Inc.
Odyssey Group International, Inc. (OTC Pink: ODYY) is focused on developing products in the area of life-saving medical solutions. Odyssey's corporate mission is to create, acquire and accumulate distinct assets, intellectual properties, and exceptional technologies that provide meaningful solutions to unmet medical needs. The Company is focused on technologies that have an identified technological advantage, provide superior clinical utility, have a substantial market opportunity.
We encourage our shareholders to visit: http://www.odysseygi.com or Twitter: @OdysseyGroupIn1.
About PRV-002
PRV-002 is a fully synthetic non-naturally occurring neurosteroid being developed for the treatment of mTBI (concussion). In preclinical studies, PRV-002 has demonstrated equivalent, if not superior, neuroprotective effects compared to related neurosteroids. Animal models of concussion demonstrated that PRV-002 reduces the behavioral pathology associated with brain injury symptoms such as memory impairment, anxiety, and motor/sensory performance. Additionally, PRV-002 is lipophilic and can easily cross the blood-brain barrier to rapidly eliminate swelling, oxidative stress and inflammation in the brain while restoring proper blood flow. PRV-002 is currently in a Phase 1 clinical trial.
Forward-Looking Statements
This news release may contain forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including our ability to continue to raise needed funds, successfully complete the phase 1 trial, our ability to successfully develop products, rapid changes in our markets, changes in demand for our future products, and legislative, regulatory, competitive developments and general economic conditions.
Contact:
Odyssey Health, Inc. f/k/a Odyssey Group International, Inc.
info@odysseygi.com
Attachments
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
Odyssey Group International Announces Formation of Military Advisory Board
https://www.globenewswire.com/newsroom/ti?nf=ODUxMzM5NiM0ODI2NjgzIzUwMDA4NjI2NA==
https://ml.globenewswire.com/media/MzQxNTA4NWItMmVjZC00YTQ0LWExYzMtZGExNzM1OGUzNDVhLTUwMDA4NjI2NA==/tiny/Odyssey-Group-Intl-Inc-.png
Odyssey Group International Announces Formation of Military Advisory Board
James “Jim” Linder: Major General USA (r) Former Chief of Staff USSOCOM
Odyssey Group International Announces Formation of Military Advisory Board
Francis Beaudette: Commanding General US Army Special Operations Command (r)
Odyssey Group International Announces Formation of Military Advisory Board
Paul Toolan: Lieutenant Colonel (r)
Source: Odyssey Group Intl Inc.
© 2022 GlobeNewswire, Inc.
Brett Favre MUST SEE VIDEO $ODYY!!
Brett Favre MUST SEE VIDEO $ODYY!!!
Brett Favre MUST SEE VIDEO $ODYY!!
I think we get back to that $1.00 level. $ODYY JMHO
TBT thanks for the heads up on $BLLB. It's been added